Felicitex Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • PE Growth
  • Financing Rounds
  • 2

Felicitex Therapeutics General Information

Description

Operator of a drug discovery platform dedicated to developing novel treatments for dormant cancers. The company offers treatments that target both dormant and proliferating cancers and will improve the effectiveness and long-term outcomes of treatments for the deadliest and most therapy-resistant liquid and solid tumors such as hematopoietic, ovarian, pancreatic, colorectal, osteosarcoma, glioblastoma and lungs, enabling patients to recover in a better and effective way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 27 Strathmore Road
  • Natick, MA 01760
  • United States
+1 (919) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Felicitex Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Felicitex Therapeutics‘s full profile, request access.

Request a free trial

Felicitex Therapeutics Patents

Felicitex Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10577365-B2 Derivatives of quinoline as inhibitors of dyrk1a and/or dyrk1b kinases Active 23-Dec-2016 0000000000
US-20180179199-A1 Derivatives of quinoline as inhibitors of dyrk1a and/or dyrk1b kinases Granted 23-Dec-2016 0000000000
JP-2020502252-A Derivatives of quinoline as inhibitors of dyrk1a and / or dyrk1b kinase Pending 23-Dec-2016 0000000000
EP-3558321-A1 Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases Pending 23-Dec-2016 0000000000
EP-3558321-A4 Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases Pending 23-Dec-2016 C07D471/04 0

Felicitex Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Maria Vilenchik Ph.D Co-Founder & Chief Executive Officer
Michael Frid Ph.D Co-Founder, Head of Preclinical Pharmacology & Vice President, Pre-Clinical Research
To view Felicitex Therapeutics’s complete executive team members history, request access »

Felicitex Therapeutics Board Members (5)

Name Representing Role Since
0000 000000000000 00.0 Self Board Member & Scientific Advisor 000 0000
0000 0000 Felicitex Therapeutics Chairman 000 0000
0000 00000 00.0 Self Board Member & Scientific Advisor 000 0000
0000000 0000000000 00.0 Self Board Member & Scientific Advisor 000 0000
00000 000000 00.0 Self Co-Founder, Scientific Advisor & Board Member 000 0000
To view Felicitex Therapeutics’s complete board members history, request access »

Felicitex Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Felicitex Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Felicitex Therapeutics‘s full profile, request access.

Request a free trial